William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating on March 11.
Matt Phipps has given his Buy rating due to a combination of factors that highlight Genmab’s promising prospects. The company has presented encouraging data for Rina-S, particularly in terms of overall response rate and duration of response, which remain robust across various FRα expression levels. This strong performance was showcased at the Society of Gynecologic Oncology Annual Meeting, reinforcing the potential of Rina-S in the oncology landscape.
Moreover, Genmab is positioned for significant growth with several key catalysts anticipated in the coming years. These include pivotal results from ongoing studies, such as the Phase III trials for Rina-S in endometrial and ovarian cancers, and Epkinly in lymphoma. The company’s strategic advancements, coupled with the recent clearance of a major decision involving Johnson & Johnson, present an attractive buying opportunity for investors looking to capitalize on Genmab’s future developments.
In another report released on March 11, Truist Financial also maintained a Buy rating on the stock with a $45.00 price target.